The Mayo Alliance Prognostic System (MAPS) for SM developed a prognostic score in which the presence of adverse mutations (ASXL1/RUNX1/NRAS) was recognized as an independent risk factor [14]. Here, RUNX1 is linked to systemic mastocytosis.